This country code will remain if no action is taken to change it.
Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.
The Pgp-Glo™ Assay Systems provide the necessary reagents for performing luminescent P-glycoprotein (Pgp) ATPase assays. Pgp, also known as MDR1 and ABCB1, is a 170kDa integral plasma membrane protein that functions as an ATP-dependent drug efflux pump and plays an important role in multidrug resistance and certain adverse drug-drug interactions. Compounds that interact with Pgp can be identified as stimulators or inhibitors of its ATPase activity. Compounds that are substrates for transport by Pgp typically stimulate its ATPase activity.
The Pgp-Glo™ Assay detects the effects of compounds on recombinant hu...
Expand to Read More »
The Pgp-Glo™ Assay detects the effects of compounds on recombinant human Pgp in a cell membrane fraction. The assay relies on the ATP dependence of the light-generating reaction of firefly luciferase. ATP is first incubated with Pgp; then the Pgp ATPase reaction is stopped, and the remaining unmetabolized ATP is detected as a luciferase-generated luminescent signal. Pgp-dependent decreases in luminescence reflect ATP consumption by Pgp; thus the greater the decrease in signal, the higher the Pgp activity. Accordingly, samples containing compounds that stimulate the Pgp ATPase will have significantly lower signals than untreated samples.
« Collapse Content
Pgp-Glo™ Assay System
Pgp-Glo™ Assay Buffer
ATP Detection Buffer
ATP Detection Substrate
Pgp-Glo™ Assay System with P-glycoprotein
Human Pgp Membranes, Recombinant
Store Recombinant Human Pgp Membranes at –70°C. All other components can be stored at –70°C or –20°C, protected from light.
For product intended use please see Patents & Disclaimers tab.
Stimulation of Pgp ATPase activity by verapamil. NT=not treated. TC=test compound.
V3591, V3601 For Research Use Only. Not for Use in Diagnostic Procedures.
V3591, V3601 Patent Pending.
V3591, V3601 The method of recombinant expression of Coleoptera luciferase is covered by U.S. Pat. Nos. 5,583,024, 5,674,713 and 5,700,673.
View All Reviews »
Review This Product »
We offer a range of services to help you succeed using Promega technologies. From product training to set up of automated systems and development of custom applications—our scientific support goes beyond the basics.
Ask us! We are here to help you.